New first-line option for metastatic pancreatic cancer

John asks what NAPOLI‑3 is and explains nalirifox (liposomal irinotecan + 5‑FU + oxaliplatin) and its trial context.

Play episode from 00:25

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!